Biotech Top Gainers: Genetic Technologies Limited (NASDAQ:GENE), Esperion Therapeutics (NASDAQ:ESPR), Can-Fite BioPharma (NYSEMKT:CANF), Egalet Corporation (NASDAQ:EGLT), Evogene (NYSE:EVGN)

On 29 January Genetic Technologies Limited (NASDAQ: GENE) reported that up to 6 new breast diagnosis/treatment centres are expected to begin offering BREVAGenplus® to their at-risk patients in a systematic broad fashion in the January to March timeframe, with a growing number of additional new breast and imaging centre customers expected to follow later in calendar year 2015. As a result, the Company expects sales growth to accelerate in the second half 2015 and beyond. On Wednesday shares of Genetic Technologies Limited (NASDAQ:GENE) closed at $3.53. Company’s sales growth for last 5 years was -16.50%.

Esperion Therapeutics, Inc. (NASDAQ: ESPR), on 2 February announced the U.S. Food and Drug Administration (FDA) has removed the peroxisome proliferator-activated receptor (PPAR) partial clinical hold on ETC-1002. Esperion Therapeutics, Inc. (NASDAQ:ESPR) in last trading activity advanced 6.24% to close at $55.01. Company weekly performance is 20.48% while its quarterly performance stands at 90.68%. Esperion Therapeutics, Inc. (NASDAQ:ESPR) is -0.87% away from its 52 week high.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) announced that all patients enrolled in its Phase II/III psoriasis trial for the Company’s drug candidate CF101 have completed the study’s 32 week treatment protocol. On last trading day Can-Fite BioPharma Ltd. (NYSEMKT:CANF) advanced 7.40% to close at $3.63. Its volatility for the week is 6.64% while volatility for the month is 7.05%. Can-Fite BioPharma Ltd. (NYSEMKT:CANF) monthly performance is -5.22%.

Egalet Corporation (NASDAQ:EGLT) on 22 January announced positive results from a Category 3 human abuse liability (HAL) study of Egalet-001, an abuse-deterrent, extended-release, oral morphine formulation in late-stage clinical development for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. Egalet Corporation (NASDAQ:EGLT) has 3.80% insider ownership while its institutional ownership stands at 68.30%. In last trading activity company’s stock closed at $9.95.

Evogene Ltd. (NYSE:EVGN) announced that its recently developed comprehensive gene optimization program is being incorporated into its multi-year collaboration with Monsanto Company On last trading day Evogene Ltd. (NYSE:EVGN) advanced 10.27% to close at $9.34. Its volatility for the week is 1.78% while volatility for the month is 2.65%. Evogene Ltd. (NYSE:EVGN) monthly performance is -0.53%.

Biotech Unusual Volume: Genetic Technologies Limited (NASDAQ:GENE), Hemispherx Biopharma (NYSEMKT:HEB), Esperion Therapeutics (NASDAQ:ESPR), Onconova Therapeutics (NASDAQ:ONTX), Ardelyx (NASDAQ:ARDX)

Genetic Technologies Limited (NASDAQ:GENE) on 29 January reported that it has entered into a A$24 million Standby Equity Placement Facility Agreement with the Kentgrove Capital Growth Fund to strengthen the Company’s funding position. On Tuesday shares of Genetic Technologies Limited (NASDAQ:GENE) closed at $3.09. Company’s sales growth for last 5 years was -16.50%.

Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced the results of a new efficacy study of Ampligen® in a mouse model of Ebola virus (EBOV) infection performed by scientists at the U.S. Army Medical Research Institute of Infectious Disease (USAMRIID).Hemispherx Biopharma, Inc. (NYSEMKT:HEB) in last trading activity decreased -13.20% to close at $0.26. Company weekly performance is 18.36% while its quarterly performance stands at -10.21%. Hemispherx Biopharma, Inc. (NYSEMKT:HEB) is -46.86% away from its 52 week high.

Esperion Therapeutics (NASDAQ:ESPR) announced that the FDA has removed the peroxisome proliferator-activated receptor partial clinical hold on ETC-1002.On last trading day Esperion Therapeutics, Inc. (NASDAQ:ESPR) moved up 15.61% to close at $51.78. Its volatility for the week is 9.81% while volatility for the month is 8.73%. ESPR’s EPS growth for past 5 years was -29.50%. Esperion Therapeutics, Inc. (NASDAQ:ESPR) monthly performance is 25.59%.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced that following discussions regarding the future development of rigosertib with the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and several European national regulatory agencies, the Company has solidified its plans for a Phase 3 clinical trial for rigosertib in HR-MDS patients after failure of treatment with HMAs. Pending regulatory approvals and appropriate financing, Onconova hopes to initiate trial enrollment during the second half of 2015. Onconova Therapeutics, Inc. (NASDAQ:ONTX) has 62.56% insider ownership while its institutional ownership stands at 9.50%. In last trading activity company’s stock closed at $2.55.

Ardelyx, Inc. (NASDAQ:ARDX), announced that AstraZeneca’s 161-patient Phase 2b clinical trial evaluating tenapanor in hyperphosphatemic patients with chronic kidney disease on hemodialysis met its primary endpoint by demonstrating a statistically significant dose-related decrease in serum phosphate levels for tenapanor-treated patients compared to patients receiving placebo (p=0.012). On last trading day Ardelyx, Inc. (NASDAQ:ARDX) decreased -19.27% to close at $15.54. Its volatility for the week is 16.71% while volatility for the month is 8.64%. Ardelyx, Inc. (NASDAQ:ARDX) monthly performance is -23.30%.

Biotech Losers: Xenoport (NASDAQ:XNPT), Onconova Therapeutics (NASDAQ:ONTX), Advaxis (NASDAQ:ADXS), Regado Biosciences (NASDAQ:RGDO), Omeros Corporation (NASDAQ:OMER)

XenoPort, Inc. (NASDAQ: XNPT) on 29 January announced the pricing of $100 million aggregate principal amount of 2.50% Convertible Senior Notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A (the “offering”) under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, XenoPort also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $15 million aggregate principal amount of the notes to cover over-allotments, if any.On Tuesday shares of Xenoport, Inc. (NASDAQ:XNPT) closed at $7.36. Company’s sales growth for last 5 years was -28.20% and EPS growth for next 5 years is recorded as 5.00%.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced that following discussions regarding the future development of rigosertib with the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and several European national regulatory agencies, the Company has solidified its plans for a Phase 3 clinical trial for rigosertib in HR-MDS patients after failure of treatment with HMAs. Onconova Therapeutics, Inc. (NASDAQ:ONTX) in last trading activity decreased -36.41% to close at $2.55. Company weekly performance is -29.56% while its quarterly performance stands at -47.53%. Onconova Therapeutics, Inc. (NASDAQ:ONTX) is -83.44% away from its 52 week high.

An investigation on behalf of investors of Advaxis, Inc. (NASDAQ:ADXS) shares over potential securities laws violations by Advaxis, Inc. and certain of its directors and officers in connection certain financial statements was announced on 26 January. On last trading day Advaxis, Inc. (NASDAQ:ADXS) decreased -8.96% to close at $8.74. Its volatility for the week is 13.95% while volatility for the month is 16.79%. ADXS’s EPS growth for past 5 years was -24.50%. Advaxis, Inc. (NASDAQ:ADXS) monthly performance is 3.80%.

On Thursday, January 23, 2015, Regado Biosciences, Inc., (NASDAQ:RGDO) a Delaware corporation Landmark Merger Sub, Inc., a Delaware corporation (“Merger Sub”), Tobira Therapeutics, Inc., a Delaware corporation (“Tobira”) and Brent Ahrens as the Company Stockholders’ Agent (the “Stockholders’ Agent”) entered into an amendment (the “Amendment”) to the Agreement and Plan of Merger and Reorganization dated as of January 14, 2015 between the Company, Merger Sub, Tobira and the Stockholders’ Agent (the “Merger Agreement”). Pursuant to the Merger Agreement, as amended by the Amendment, Merger Sub will be merged with and into Tobira (the “Merger”), with Tobira surviving the Merger as a wholly-owned subsidiary of the Company. Regado Biosciences, Inc. (NASDAQ:RGDO) has 9.60% insider ownership while its institutional ownership stands at 47.30%. In last trading activity company’s stock closed at $1.21.

Omeros Corporation (NASDAQ: OMER) announced that it has closed the underwritten public offering that was priced and allocated to investors on January 28, 2015 relating to the sale of 3,444,831 shares of its common stock at a price of $20.03 per share and 749,250 pre-funded warrants to purchase up to an equal number of shares of its common stock at a price per warrant of $20.02, which was paid at closing. On last trading day Omeros Corporation (NASDAQ:OMER) decreased -6.57% to close at $19.20. Its volatility for the week is 10.11% while volatility for the month is 6.41%. OMER’s sales growth for past 5 years was 5.90% and its EPS growth for past 5 years was 30.00%. Omeros Corporation (NASDAQ:OMER) monthly performance is -23.23%.

Biotech Gainers: Genetic Technologies Limited (NASDAQ:GENE), Esperion Therapeutics (NASDAQ:ESPR), Theravance Inc. (NASDAQ:THRX), RXi Pharmaceuticals Corporation (NASDAQ:RXII), Recro Pharma (NASDAQ:REPH)

Genetic Technologies Limited (NASDAQ:GENE) on 29 January announced that up to 6 new breast diagnosis/treatment centers are expected to begin offering BREVAGenplus? to their at-risk patients in a systematic broad fashion in the January to March timeframe, with a growing number of additional new breast and imaging center customers expected to follow later in calendar year 2015. As a result, the Company expects sales growth to accelerate in the second half 2015 and beyond. On Tuesday shares of Genetic Technologies Limited (NASDAQ:GENE) closed at $3.09. Company’s sales growth for last 5 years was -16.50%.

Esperion Therapeutics, Inc. (NASDAQ: ESPR), announced the U.S. Food and Drug Administration (FDA) has removed the peroxisome proliferator-activated receptor (PPAR) partial clinical hold on ETC-1002. Esperion Therapeutics, Inc. (NASDAQ:ESPR) in last trading activity increased 15.61% to close at $51.78. Company weekly performance is 9.89% while its quarterly performance stands at 77.03%. Esperion Therapeutics, Inc. (NASDAQ:ESPR) is 4.19% away from its 52 week high.

Zacks reaffirmed their neutral rating on shares of Theravance (NASDAQ:THRX) in a report released on Tuesday. Zacks currently has a $13.00 price objective on the stock. On last trading day Theravance Inc. (NASDAQ:THRX) increased 11.89% to close at $11.95. Its volatility for the week is 8.03% while volatility for the month is 6.43%. THRX’s sales growth for past 5 years was -27.00% and its EPS growth for past 5 years was -1.80%. Theravance Inc. (NASDAQ:THRX) monthly performance is -13.84%.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) announced that it has been granted a patent by the United States Patent and Trademark Office (USPTO) for the delivery of double stranded siRNAs (21 to 23 nucleotides in length) across the blood-retina barrier (e.g. topical or systemic delivery) for the treatment of wet age-related macular degeneration or diabetic retinopathy. The patent, part of RXi’s acquired OPKO estate, is scheduled to expire in 2023. RXi Pharmaceuticals Corporation (NASDAQ:RXII) has 6.10% insider ownership while its institutional ownership stands at 13.50%. In last trading activity company’s stock closed at $1.18.

Recro Pharma, Inc. (NASDAQ:REPH), announced it has entered into a common stock purchase agreement with Aspire Capital Fund, LLC (“Aspire Capital”). Under the new agreement, Recro has the right to sell up to $10 million in shares of common stock to Aspire Capital, subject to certain terms and conditions over a two-year period.On last trading day Recro Pharma, Inc. (NASDAQ:REPH) increased 13.17% to close at $3.18. Its volatility for the week is 5.65% while volatility for the month is 5.26%. Recro Pharma, Inc. (NASDAQ:REPH) monthly performance is 9.66%.

Biotech Bears: Amicus Therapeutics (NASDAQ:FOLD), Genetic Technologies Limited (NASDAQ:GENE), Ardelyx (NASDAQ:ARDX), Enanta Pharmaceuticals (NASDAQ:ENTA), Spark Therapeutics (NASDAQ:ONCE)

Amicus Therapeutics (NASDAQ:FOLD), announced that 2 oral presentations and 6 posters highlighting its development programs for lysosomal storage diseases will be included at the 11th Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD), to be held February 9-13, 2015 in Orlando, FL.On Monday shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) closed at $7.24. Company’s sales growth for last 5 years was -51.60%.

Genetic Technologies Limited (NASDAQ:GENE) on 29 January announced that up to 6 new breast diagnosis/treatment centers are expected to begin offering BREVAGenplus? to their at-risk patients in a systematic broad fashion in the January to March timeframe, with a growing number of additional new breast and imaging center customers expected to follow later in calendar year 2015. As a result, the Company expects sales growth to accelerate in the second half 2015 and beyond. Genetic Technologies Limited (NASDAQ:GENE) in last trading activity moved down -7.17% to close at $2.59. Company weekly performance is 90.44% while its quarterly performance stands at 17.73%. Genetic Technologies Limited (NASDAQ:GENE) is -78.51% away from its 52 week high.

Ardelyx Inc (NASDAQ:ARDX) said its experimental drug significantly decreased phosphate levels in chronic kidney disease patients who were on dialysis. On last trading day Ardelyx, Inc. (NASDAQ:ARDX) moved down -28.73% to close at $19.25. Its volatility for the week is 12.85% while volatility for the month is 7.75%. Ardelyx, Inc. (NASDAQ:ARDX) monthly performance is 1.91%.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), announced topline Phase 3 results from the GIFT-1 study, AbbVie’s investigational, all-oral, ribavirin-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has 4.70% insider ownership while its institutional ownership stands at 84.20%. In last trading activity company’s stock closed at $39.08.

Spark Therapeutics Inc. (NASDAQ:ONCE) announced on 30 January the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $23.00 per share, before underwriting discounts. On last trading day Spark Therapeutics, Inc. (NASDAQ:ONCE) moved down -8.00% to close at $46.00.

Biotech Bulls: Curis (NASDAQ:CRIS), CorMedix (NYSEMKT:CRMD), Theravance Biopharma (NASDAQ:TBPH), GenVec (NASDAQ:GNVC), Genocea Biosciences (NASDAQ:GNCA)

On 21st January Curis, Inc. (NASDAQ:CRIS), and Aurigene Discovery Technologies Limited, announced that they have entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets. On Monday shares of Curis, Inc. (NASDAQ:CRIS) closed at $1.95. Company’s sales growth for last 5 years was 12.30%.

CorMedix Inc. (NYSE MKT: CRMD), on 29 January announced that the U.S. Food and Drug Administration (FDA) has designated the company’s lead product candidate, Neutrolin® Catheter Lock Solution, as a Qualified Infectious Disease Product (QIDP) for oncology, hemodialysis and intensive care unit patients, where catheter-related blood stream infections and clotting can be life-threatening. CorMedix, Inc. (NYSEMKT:CRMD) in last trading activity increased 6.45% to close at $3.30. Company weekly performance is 47.98% while its quarterly performance stands at 80.33%. CorMedix, Inc. (NYSEMKT:CRMD) is -0.60% away from its 52 week high.

Theravance Biopharma, Inc. (NASDAQ:TBPH) and Mylan Inc. announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases. On last trading day Theravance Biopharma, Inc. (NASDAQ:TBPH) increased 6.96% to close at $17.37. Its volatility for the week is 7.29% while volatility for the month is 5.50%. Theravance Biopharma, Inc. (NASDAQ:TBPH) monthly performance is 16.42%.

GenVec, Inc. (NASDAQ:GNVC) announced that its President and CEO, Douglas J. Swirsky, will present a corporate overview at the 17th Annual BIO CEO & Investor Conference at 1 p.m. EST on Monday, February 9, 2015 at the Waldorf Astoria Hotel in New York City. GenVec, Inc. (NASDAQ:GNVC) has 1.50% insider ownership while its institutional ownership stands at 33.50%. In last trading activity company’s stock closed at $3.88.

Genocea Biosciences, Inc. (NASDAQ: GNCA), announced that Chip Clark, president and chief executive officer, will present a company overview at the upcoming 2015 BIO CEO & Investor Conference. The presentation is scheduled for Monday, February 9, 2015 at 8:30 a.m. EST in New York, NY. On last trading day Genocea Biosciences, Inc. (NASDAQ:GNCA) advanced 9.09% to close at $9.36. Its volatility for the week is 10.72% while volatility for the month is 7.11%. Genocea Biosciences, Inc. (NASDAQ:GNCA) monthly performance is 33.71%.

Biotech Volatile Stocks: ImmunoGen (NASDAQ:IMGN), Genetic Technologies Limited (NASDAQ:GENE), TrovaGene (NASDAQ:TROV), Repligen Corporation (NASDAQ:RGEN), Vitae Pharmaceuticals (NASDAQ:VTAE)

ImmunoGen, Inc. (NASDAQ:IMGN) reported fiscal second quarter earnings. The company announced net income of $13.6 million, or $0.16 per share, substantially -$0.21- above Capital IQ’s Consensus Estimate of a $0.05 per share loss, and also up from the same quarter last year, which saw net income of $3.8 million, or $0.04 per share. On Friday shares of ImmunoGen, Inc. (NASDAQ:IMGN) closed at $7.63. Company’s sales growth for last 5 years was 16.40%.

Genetic Technologies Limited (NASDAQ: GENE) on 21st January announced that it has entered into a A$24 million Standby Equity Placement Facility Agreement (the “Facility” or “Agreement”) with the Kentgrove Capital Growth Fund (“Kentgrove Capital”), an investment fund managed by Kentgrove Capital Pty Ltd, a Melbourne-based investment and advisory firm, to strengthen the Company’s funding position.Genetic Technologies Limited (NASDAQ:GENE) in last trading activity moved down -22.71% to close at $2.79. Company weekly performance is 123.20% while its quarterly performance stands at 24.00%. Genetic Technologies Limited (NASDAQ:GENE) is -76.85% away from its 52 week high.

TrovaGene Inc. (NASDAQ:TROV) recently announced a number of collaborations with eminent research institutes around the world. The tie-ups aim at evaluating the efficiency of the company’s Precision Cancer Monitoring system in detecting and monitoring different mutations. On last trading day TrovaGene, Inc. (NASDAQ:TROV) moved up 11.49% to close at $6.50. Its volatility for the week is 8.18% while volatility for the month is 8.97%. TrovaGene, Inc. (NASDAQ:TROV) monthly performance is 51.16%.

Repligen Corporation (NASDAQ:RGEN) announced on 21st January that its Board of Directors has appointed Tony J. Hunt to be the Company’s next Chief Executive Officer. Mr. Hunt, currently Repligen’s Chief Operating Officer, will succeed Walter C. Herlihy, Ph.D., who will retire as President and CEO effective May 21, 2015, the date of the Company’s Annual Meeting of Stockholders. Repligen Corporation has 1.80% insider ownership while its institutional ownership stands at 90.70%. In last trading activity company’s stock closed at $24.29.

Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), on 28 January announced the closing of its previously announced underwritten public offering. A total of 3,450,000 shares of its common stock were sold in the offering at a price to the public of $11.90 per share. On last trading day Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) moved down -5.39% to close at $14.57. Its volatility for the week is 11.49% while volatility for the month is 10.26%. Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) monthly performance is -13.63%.

Biotech Bearish Stocks: Genetic Technologies Limited (NASDAQ:GENE), EPIRUS Biopharmaceuticals (NASDAQ:EPRS), TRACON Pharmaceuticals (NASDAQ:TCON), bluebird bio (NASDAQ:BLUE), Xenoport (NASDAQ:XNPT)

Genetic Technologies Limited (NASDAQ:GENE) on 29 January announced that up to 6 new breast diagnosis/treatment centers are expected to begin offering BREVAGenplus? to their at-risk patients in a systematic broad fashion in the January to March timeframe, with a growing number of additional new breast and imaging center customers expected to follow later in calendar year 2015. As a result, the Company expects sales growth to accelerate in the second half 2015 and beyond. On Friday shares of Genetic Technologies Limited (NASDAQ:GENE) closed at $2.79. Company’s sales growth for last 5 years was -16.80%.

EPIRUS Biopharmaceuticals Inc. (NASDAQ:EPRS) announced the pricing of an underwritten public offering of 9.6 million shares of its common stock offered at a price to the public of $5.00 per share. Net proceeds to EPIRUS from this offering are expected to be approximately $44.2 million after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) in last trading activity moved down -7.99% to close at $4.95. Company weekly performance is -21.43% while its quarterly performance stands at 0.61%. EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) is -71.55% away from its 52 week high.

TRACON Pharmaceuticals Inc. (NASDAQ:TCON) raised $36 million by offering 3.6 million shares at $10, well below the $12 to $14 range. On last trading day TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) moved down -6.00% to close at $9.40.

bluebird bio, Inc. (NASDAQ:BLUE) on 29 January announced that Mitchell H. Finer, Ph.D., chief scientific officer (CSO), has decided to transition from his current role with bluebird bio over the next six months. bluebird bio, Inc. (NASDAQ:BLUE) has 0.90% insider ownership while its institutional ownership stands at 88.90%. In last trading activity company’s stock closed at $92.91.

XenoPort, Inc. (NASDAQ:XNPT) announced on 29 Jnauary the pricing of $100 million aggregate principal amount of 2.50% Convertible Senior Notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A (the “offering”) under the Securities Act of 1933, as amended (the “Securities Act”).On last trading day Xenoport, Inc. (NASDAQ:XNPT) moved down -6.40% to close at $8.33. Its volatility for the week is 6.15% while volatility for the month is 6.72%. XNPT’s sales growth for past 5 years was -28.20% and its EPS growth for past 5 years was 6.10%. Xenoport, Inc. (NASDAQ:XNPT) monthly performance is -5.02%.

Biotech Bullish Stocks: ImmunoGen (NASDAQ:IMGN), Spark Therapeutics (NASDAQ:ONCE), Biogen Idec Inc. (NASDAQ:BIIB), Regado Biosciences (NASDAQ:RGDO), CorMedix (NYSEMKT:CRMD)

For the Company’s quarter ended December 31, 2014 (2Q, FY2015), ImmunoGen Inc. (NASDAQ:IMGN) reported net income of $13.6 million, or $0.16 per basic and diluted share, compared to net income of $3.8 million, or $0.04 per basic and diluted share, for the same quarter last year (2Q, FY2014). On Friday shares of ImmunoGen, Inc. (NASDAQ:IMGN) closed at $7.63. Company’s sales growth for last 5 years was 16.40%.

Spark Therapeutics Inc. (NASDAQ:ONCE) announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $23.00 per share, before underwriting discounts. All of the shares in the offering are being sold by Spark. In addition, Spark has granted the underwriters an option to purchase up to 1,050,000 additional shares of common stock at the public offering price, less the underwriting discount. Spark Therapeutics, Inc. (NASDAQ:ONCE) in last trading activity moved up 117.39% to close at $50.00.

Biogen Idec Inc. (NASDAQ:BIIB) on 29 January reported fourth quarter non-GAAP EPS of $4.09 up from $2.34 last year. Analysts expected EPS of $3.78. Full year 2015 non-GAAP EPS is expected to be between $16.60 and $17.00. The consensus estimate is for EPS of $16.37. On last trading day Biogen Idec Inc. (NASDAQ:BIIB) moved up 10.17% to close at $389.16. Its volatility for the week is 3.28% while volatility for the month is 3.35%. BIIB’s sales growth for past 5 years was 11.10% and its EPS growth for past 5 years was 24.10%. Biogen Idec Inc. (NASDAQ:BIIB) monthly performance is 13.73%.

On Thursday, January 23, 2015, Regado Biosciences, Inc., (NASDAQ:RGDO) a Delaware corporation (the “Company”), Landmark Merger Sub, Inc., a Delaware corporation (“Merger Sub”), Tobira Therapeutics, Inc., a Delaware corporation (“Tobira”) and Brent Ahrens as the Company Stockholders’ Agent (the “Stockholders’ Agent”) entered into an amendment (the “Amendment”) to the Agreement and Plan of Merger and Reorganization dated as of January 14, 2015 between the Company, Merger Sub, Tobira and the Stockholders’ Agent (the “Merger Agreement”). Regado Biosciences, Inc. (NASDAQ:RGDO) has 9.60% insider ownership while its institutional ownership stands at 47.30%. In last trading activity company’s stock closed at $1.23.

CorMedix Inc. (NYSEMKT:CRMD), on 29 January announced that the U.S. Food and Drug Administration (FDA) has designated the company’s lead product candidate, Neutrolin® Catheter Lock Solution, as a Qualified Infectious Disease Product (QIDP) for oncology, hemodialysis and intensive care unit patients, where catheter-related blood stream infections and clotting can be life-threatening. On last trading day CorMedix, Inc. (NYSEMKT:CRMD) moved up 9.15% to close at $3.10. Its volatility for the week is 12.62% while volatility for the month is 10.51%. CRMD’s EPS growth for past 5 years was 4.10%. CorMedix, Inc. (NYSEMKT:CRMD) monthly performance is 67.57%.

Biotech Top Gainers: Genetic Technologies Limited (NASDAQ:GENE), CorMedix (NYSEMKT:CRMD), Atara Biotherapeutics (NASDAQ:ATRA), Omeros Corporation (NASDAQ:OMER), Cleveland BioLabs (NASDAQ:CBLI)

Genetic Technologies Limited (NASDAQ: GENE) is pleased to report that up to 6 new breast diagnosis/treatment centres are expected to begin offering BREVAGenplus® to their at-risk patients in a systematic broad fashion in the January to March timeframe, with a growing number of additional new breast and imaging centre customers expected to follow later in calendar year 2015. As a result, the Company expects sales growth to accelerate in the second half 2015 and beyond. On Thursday shares of Genetic Technologies Limited (NASDAQ:GENE) closed at $3.61. Company’s sales growth for last 5 years was -16.80%.

CorMedix Inc. (NYSE MKT: CRMD), on 15 January was pleased to announce that the U.S. Food and Drug Administration (FDA) granted its request for Fast Track designation of its lead product candidate, Neutrolin® Catheter Lock Solution, pursuant to the Food and Drug Administration Safety and Innovation Act (FDASIA). CorMedix, Inc. (NYSEMKT:CRMD) in last trading activity advanced 22.94% to close at $2.84. Company weekly performance is 26.67% while its quarterly performance stands at 56.04%. CorMedix, Inc. (NYSEMKT:CRMD) is -11.25% away from its 52 week high.

On January 16, 2015, the Compensation Committee of the Board of Directors of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) approved discretionary cash bonus payments to its principal executive officer, principal financial officer and named executive officers in recognition of the Company’s performance during 2014. On last trading day Atara Biotherapeutics, Inc. (NASDAQ:ATRA) increased 7.47% to close at $24.45. Its volatility for the week is 7.86% while volatility for the month is 7.11%. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) monthly performance is -9.75%.

Omeros Corporation (NASDAQ: OMER) announced that it has priced an underwritten public offering of 2,995,506 shares of its common stock at a per share price to the public equal to $20.03, and pre-funded warrants to purchase up to 749,250 shares of its common stock, at a per warrant price to the public equal to $20.02. Omeros Corporation (NASDAQ:OMER) has 4.70% insider ownership while its institutional ownership stands at 41.80%. In last trading activity company’s stock closed at $23.36.

Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced the appointment of Elena Kasimova of BioProcess Capital Partners to the Company’s Board of Directors. Ms. Kasimova was appointed pursuant to a Rights Agreement with Dr. Mikhail Mogutov, which was entered into in connection with a private sale of securities to Dr. Mogutov in June 2014. On last trading day Cleveland BioLabs, Inc. (NASDAQ:CBLI) advanced 13.48% to close at $4.21. Its volatility for the week is 23.40% while volatility for the month is 17.92%. CBLI’s sales growth for past 5 years was 12.60% and its EPS growth for past 5 years was 19.60%. Cleveland BioLabs, Inc. (NASDAQ:CBLI) monthly performance is -24.82%.